ReGenHeart

• Research type

  Research Study

• Full title

  Clinical development and proof of principle testing of new regenerative VEGF-D therapy for cost-effective treatment of refractory angina. A phase II randomised, double-blinded, placebo-controlled study.

• IRAS ID

  231753

• Contact name

  Seppo Yla Herttuala

• Contact email

  seppo.ylaherttuala@uef.fin

• Sponsor organisation

  Kuopio University Hospital

• Eudract number

  2017-000789-31

• Clinicaltrials.gov Identifier

  NCT03039751

• Duration of Study in the UK

  6 years, 2 months, 31 days

• Research summary

  ReGenHeart study will investigate the efficacy of VEGF-D gene product in improving symptoms and performance for patients suffering from persisting chest pain as a result of coronary artery disease and cannot be treated with coronary angioplasty or bypass surgery (Refractory Angina). Patients enrolled on the study will be randomly allocated to either receiving the gene therapy treatment or a placebo (dummy product) and the results of the two groups will be compared at the end of the study to assess the efficacy of the VEGF-D gene product.

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  21/SC/0207

• Date of REC Opinion

  11 Oct 2021

• REC opinion

  Further Information Favourable Opinion